search button
Open Access

Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone

  • Authors:
    • Alberto Ivan Salido‑Guadarrama
    • Jorge Gustavo Morales‑Montor
    • Claudia Rangel‑Escareño
    • Elizabeth Langley
    • Oscar Peralta‑Zaragoza
    • Jose Luis Cruz Colin
    • Mauricio Rodriguez‑Dorantes

  • View Affiliations

  • Published online on: April 8, 2016     https://doi.org/10.3892/mmr.2016.5095
  • Pages: 4549-4560

  • Copyright: © Salido‑Guadarrama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

At present, prostate-specific antigen (PSA) is used as a clinical biomarker for prostate cancer (PCa) diagnosis; however, a large number of patients with benign prostate hyperplasia (BPH) with PSA levels in the ʻgray areaʼ (4-10 ng/ml) are currently subjected to unnecessary biopsy due to overdiagnosis. Certain microRNAs (miRs) have been proven to be useful biomarkers, several of which are detectable in bodily fluids. The present study identified and validated a urinary miR‑based signature to enhance the specificity of PCa diagnosis and to reduce the number of patients with benign conditions undergoing biopsy. Seventy‑three urine samples from Mexican patients with diagnosis of PCa with a Gleason score ≥7 and 70 patients diagnosed with BPH were collected after digital rectal examination (DRE) of the prostate. miR expression profiles were determined using TaqMan Low Density Array experiments, and normalized Ct values for the miRs were compared between PCa and BPH groups. Receiver operating characteristic (ROC) curve analysis was performed to evaluate whether miR detection in urine is suitable for distinguishing patients with PCa from those with BPH. The identified miR‑100/200b signature was significantly correlated with PCa. Using a multivariable logistic regression approach, a base model including the clinical variables age, prostate‑specific antigen (PSA), the percentage of free PSA and DRE was generated, and a second base model additionally contained the miR‑100/200b signature. ROC analysis demonstrated that the combined model significantly outperformed the capacity of PSA (P<0.001) and the base model (P=0.01) to discriminate between PCa and BPH patients. In terms of evaluation of the sub‑group of patients in the gray zone of PSA levels, the performance of the combined model for predicting PCa cases was significantly superior to PSA level determination (P<0.001) and the base model (P=0.009). In addition, decision curve analysis demonstrated that the use of the combined model increased the clinical benefit for patients and produced a substantial reduction in unnecessary biopsies across a range of reasonable threshold probabilities (10‑50%). Detection of the urinary miR signature identified in the present study as part of clinical diagnostic procedures will enhance the accuracy of PCa diagnosis and provide a clinical benefit for patients with BPH by sparing them from undergoing invasive biopsy. To the best of our knowledge, the present study was the first to describe the profiling of urinary miR100 and miR-200b levels for the clinical diagnosis of PCa.
View Figures
View References

Related Articles

Journal Cover

June-2016
Volume 13 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 7.6
  • CiteScore Rank: Q1: #82/347 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.647
  • SCImago Journal Rank (SJR): 0.781
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Salido‑Guadarrama AI, Morales‑Montor JG, Rangel‑Escareño C, Langley E, Peralta‑Zaragoza O, Cruz Colin JL and Rodriguez‑Dorantes M: Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Mol Med Rep 13: 4549-4560, 2016.
APA
Salido‑Guadarrama, A.I., Morales‑Montor, J.G., Rangel‑Escareño, C., Langley, E., Peralta‑Zaragoza, O., Cruz Colin, J.L., & Rodriguez‑Dorantes, M. (2016). Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Molecular Medicine Reports, 13, 4549-4560. https://doi.org/10.3892/mmr.2016.5095
MLA
Salido‑Guadarrama, A. I., Morales‑Montor, J. G., Rangel‑Escareño, C., Langley, E., Peralta‑Zaragoza, O., Cruz Colin, J. L., Rodriguez‑Dorantes, M."Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone". Molecular Medicine Reports 13.6 (2016): 4549-4560.
Chicago
Salido‑Guadarrama, A. I., Morales‑Montor, J. G., Rangel‑Escareño, C., Langley, E., Peralta‑Zaragoza, O., Cruz Colin, J. L., Rodriguez‑Dorantes, M."Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone". Molecular Medicine Reports 13, no. 6 (2016): 4549-4560. https://doi.org/10.3892/mmr.2016.5095